Barclays analyst Luke Sergott raised the firm’s price target on Avantor (AVTR) to $15 from $13 and keeps an Overweight rating on the shares as part of a Q3 preview for the life science tools and diagnostics group. The firm views the companies’ end markets as stable with improvements likely going forward. In addition, investment sentiment “feels bottomed” as share valuations have come down, the analyst tells investors in a research note.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVTR:
- Avantor Appoints Emmanuel Ligner as CEO and Director
- Avantor (AVTR) in the Hot Seat as Activist Investor Presses for Big Changes or Sale
- Avantor says regularly reviews strategic priorities after activist letter
- Engine Capital confirms stake in Avantor, sends letter to board
- Engine Capital plans to push Avantor to sell itself or make changes, WSJ says